SavedAdd your journal

Journals / Ege Tıp Dergisi / 2016 / Cilt: 55 - Sayı: 1

A case of dermatomyositis with a dramatic response to IVIG treatment

IVIG tedavisine dramatik yanıt veren dermatomiyozit olgusu

Münevver OKAY
Buse Rahime HISARCI
İlknur Aydın CANTÜRK
Dilek AĞIRCAN
Abdülkadir KOÇER
Pages
32–34
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In this paper we present a twenty-six-year-old man who attended with muscle weakness, typical skin manifestations and providing a dramatic response to IVIG treatment of dermatomyositiz

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Dermatomiyozitis (DM) is an idiopathic inflammatory myopathy and a rare connective tissue disease which is characterized by skin lesions.
📊
Key Findings & Data:Diagnosis of DM requires a characteristic rash and other criteria, such as proximal muscle weakness and muscle enzyme level elevation.
💡
Conclusion & Impact:In this paper we present a twenty-six-year-old man who attended with muscle weakness, typical skin manifestations and providing a dramatic response to IVIG treatment of dermatomyositiz
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Dermatomiyozitis (DM) is an idiopathic inflammatory myopathy and a rare connective tissue disease which is characterized by skin lesions. Diagnosis of DM requires a characteristic rash and other criteria, such as proximal muscle weakness and muscle enzyme level elevation. In this paper we present a twenty-six-year-old man who attended with muscle weakness, typical skin manifestations and providing a dramatic response to IVIG treatment of dermatomyositiz

Özet

Dermatomiyozit (DM), bir idiyopatik inflamatuar miyopati ve nadir görülen bağ doku hastalıklarından olup cilt lezyonları ile karakterizedir. DM tanısı için karakteristik raşlara ilaveten proksimal kas güçsüzlüğü ve kas enzim düzeylerinin artışı gibi kriterlere gerek duyulmaktadır. Bu yazıda 26 yaşında kas güçsüzlüğü ve tipik cilt lezyonları ile başvuran ve IVIG tedavisine dramatik yanıt veren dermatomiyozit olgusu sunulmuştur

🔖

Cite This Article

OKAY, M., HISARCI, B. R., CANTÜRK, İ. A., AĞIRCAN, D., KOÇER, A. (2016). A case of dermatomyositis with a dramatic response to IVIG treatment. Ege Tıp Dergisi, Cilt: 55 - Sayı: 1, 32–34. https://ajindex.com/articles/198823

References (9)

  1. Wang DX, Shu XM, Tian XL, et al. Intravenous immunglobulin therapy in adult patients with polymyositis/dermatomyositis: a systematic literature review. Clin Rheumatol 2012;31(5):801-6
  2. Yeral M, Yüksel A, Sığanık A, Polat H, Alev A. Dermatomiyozit: Bir Olgu Sunumu. İstanbul Tıp Dergisi 2005;6(4):50-2
  3. Bronner IM, van der Meulen MF, de Visser M, et al. Long-term outcome in polymyositis and dermatomyositis. Ann Rheum Dis 2006;65(11):1456-61
  4. Miyasaka N, Hara M, Koike T, Saito T, Yamada M, Tanaka Y. Effects of intravenous immunglobulin therapy in Japanese patients with polymyositis and dermatomyositis resistant to corticosteroids: A randomized double-blind placebo-controlled trial. Mod Rheumatol 2012 Jun;22(3):382-93
  5. Miller FW. Management of inflammatory muscle disease. In: Hochberg MC (ed). Rheumatology. 5th ed. Philadelphia: Elsevier; 2011:1417-78
  6. Lundberg IE, Vencovsky J, Dani L. Polymyositis, dermatomyositis, inflammatory diseases of muscle and other myopathies. In: Bjlisma JMJ (ed). EULAR Compendium on Rheumatic Diseases. 1st. ed. London: BMJ Publ; 2009;297-313. 7. van de Vlekkert J, Hoogendijk JE, de Haan RJ, et al. Oral dexamethasone pulse therapy versus daily prednisolone in sub-acute onset myositis, a randomised clinical trial. Neuromuscul Disord 2010;20(6):382-9
  7. Roifman CM, Schaffer FM, Wachsmuth SE, Murphy G, Gelfand EW. Reversal of chronic polymyositis following intravenous immune serum globulin therapy. JAMA 1987;258(4):513-5
  8. Saito E, Koike T, Hashimoto H, et al. Efficacy of high-dose intravenous immunoglobulin therapy in Japanese patients with steroid-resistant polymyositis and dermatomyositis. Mod Rheumatol 2008;18(1):34-44
  9. Quick A, Tandan R. Mechanisms of action of intravenous immunoglobulin in inflammatory muscle disease. Curr Rheumatol Rep 2011;13:192-8.